Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Tradegate
27.06.25 | 11:18
25,020 Euro
+0,24 % +0,060
Branche
Pharma
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
24,82025,06028.06.
24,84025,06027.06.

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoALK Abello: First market launch of the adrenaline nasal spray, EURneffy, for treatment of adults and children in Germany168ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely...
► Artikel lesen
ALK-ABELLO Aktie jetzt für 0€ handeln
16.06.ALK Abello: ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025144At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented...
► Artikel lesen
08.05.ALK Abello: ITULATEK approved for treatment of children and adolescents in Canada240ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and...
► Artikel lesen
06.05.ALK Abello: Three-month interim report (Q1) 2025 (unaudited)189ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth...
► Artikel lesen
02.05.ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy4
02.05.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians1
29.04.ALK Abello: Invitation to the presentation of ALK's first quarter 2025 results on Tuesday, 6 May 20251
23.04.ALK Abello: ITULAZAX tree pollen tablet approved for treatment of children in Europe124ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged...
► Artikel lesen
03.04.ALK Abello: Grant of share-based long-term incentive instruments to members of the Board of Management and key employees1
13.03.ALK Abello: Annual General Meeting in ALK-Abelló A/S held on 13 March 20253
07.03.ALK Abello: ACARIZAX approved in Canada for treatment of young children337ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated...
► Artikel lesen
04.03.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
27.02.ALK Abello: FDA approves ODACTRA for the treatment of house dust mite allergy in young children330ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA®...
► Artikel lesen
21.02.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
19.02.ALK-Abelló projects 9%-13% revenue growth for 2025 driven by global tablet expansion1
19.02.ALK Abello: Annual General Meeting in ALK-Abelló A/S on 13 March 20252
19.02.ALK-Abello shares rise following 4Q earnings report9
19.02.ALK-Abelló A/S reports FY results3
19.02.ALK Abello: Annual report 2024: ALK delivers 15% sales growth with profits up 65%344ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent...
► Artikel lesen
12.02.ALK Abello: Invitation to the presentation of ALK's annual report 2024 on Wednesday, 19 February 20254
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1